Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
Department of Medicine, Curaleaf Clinic, London, UK.
Brain Behav. 2024 Feb;14(2):e3410. doi: 10.1002/brb3.3410.
The primary aim of this study was to assess changes in sleep-specific health-related quality of life (HRQoL) for those prescribed cannabis-based medicinal products (CBMPs) for insomnia.
A case series of UK patients with insomnia was analyzed. Primary outcomes were changes in the Single-Item Sleep-Quality Scale (SQS), Generalized Anxiety Disorder-7 (GAD-7), and EQ-5D-5L at up to 6 months from baseline. Statistical significance was identified as a p value < .050.
61 patients were included in the analysis. There was an improvement in the SQS from baseline at 1, 3, and 6 months (p < .001). There were also improvements in the EQ-5D-5L Index value and GAD-7 at 1, 3, and 6 months (p < .050). There were 28 (45.9%) adverse events recorded by 8 patients (13.1%). There were no life-threatening/disabling adverse events.
Patients with insomnia experienced an improvement in sleep quality following the initiation of CBMPs in this medium-term analysis. Fewer than 15% of participants reported one or more adverse events. However, due to the limitations of the study design, further investigation is required before definitive conclusions can be drawn on the efficacy of CBMPs in treating insomnia.
本研究的主要目的是评估那些因失眠而开大麻基药用产品（CBMP）的患者的睡眠特定健康相关生活质量（HRQoL）变化。
对英国失眠患者进行了病例系列分析。主要结局是从基线开始，在 6 个月内，使用单一项睡眠质量量表（SQS）、广泛性焦虑症-7 项量表（GAD-7）和 EQ-5D-5L 量表评估睡眠特定健康相关生活质量的变化。统计学显著性定义为 p 值<.050。
61 例患者纳入分析。SQS 从基线开始在 1、3 和 6 个月时均有改善（p<.001）。EQ-5D-5L 指数值和 GAD-7 在 1、3 和 6 个月时也有所改善（p<.050）。8 名患者（13.1%）记录了 28 次（45.9%）不良事件。没有危及生命/致残的不良事件。
在这项中期分析中，失眠患者在开始使用大麻基药用产品后，睡眠质量得到改善。不到 15%的参与者报告了一个或多个不良事件。然而，由于研究设计的限制，在明确 CBMP 治疗失眠的疗效之前，还需要进一步的调查。
